AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 272 min read$GMAB

J.P. Morgan upgrades Genmab on cancer drug growth potential

J.P. Morgan upgraded Genmab to 'overweight' and raised its price target to DKr3,500, citing expected positive results from a late-stage trial of its cancer drug petosemtamab. The brokerage anticipates a response rate of at least 40% in head and neck cancer patients, raising its peak sales forecast to $5 billion. It also increased sales forecasts for other drugs, Rina-S and Epkinly, and adjusted its revenue and earnings per share estimates.

Original reporting
finance.yahoo.com
Published Oct 27, 2026, 11:11 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 11:24 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB
Relevance
8/10
AlphAI data visualization · based on finance.yahoo.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The upgrade and raised price target suggest near‑term upside, but the outcome of the Phase III trial remains a key risk.

02

Market read

Analyst upgrade with new trial expectations provides a fresh trading catalyst for GMAB.

03

What to watch

Execution risk of the trial and competitive landscape for head‑and‑neck cancer therapies.

Relevance 8/10Novelty 8/10Timing: today

Background

Genmab is a Danish biotech listed on Nasdaq (GMAB) developing oncology drugs. The upgrade follows J.P. Morgan's analysis of upcoming trial data.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

J.P. Morgan upgraded Genmab to overweight, raised price target and highlighted upcoming Phase III trial data for petosemtamab.

Expected impact

likely upside as market prices in the upgrade and trial optimism

Evidence & confidence

Upgrade is fresh, includes new price target and trial expectations; traders can act on the bullish view today.

Market effects

Sector

Positive sentiment may lift other biotech stocks awaiting late‑stage trial data.

Regional

European biotech sector could see modest gains as a Danish firm receives a major upgrade.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If the Phase III trial fails to meet expectations, the upgrade could reverse quickly.

Key entities

  • company
    Genmab A/S

    Biotechnology firm developing petosemtamab and other oncology candidates.

  • analyst
    J.P. Morgan

    Upgraded Genmab to overweight and increased price target.

Read at source← All news

StoryJPMorgan upgrades Genmab to Overweight and raises price target to DKK3,500

Related articles

OCT 26
$GMABMedAI 8/10

Genmab A/S Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival With Petosemtamab Plus Pembrolizumab In First-Line Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma

Genmab A/S reported updated Phase 2 trial data for petosemtamab plus pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma. The combination achieved a median overall survival of 28.2 months, an overall response rate of 63%, and a median progression-free survival of 9.0 months. The findings were presented at the ESMO Congress 2026. The company is also conducting four Phase 3 trials for petosemtamab in various cancer types.

marketscreener.com5 min
OCT 26
$GMABMedAI 8/10

Genmab's Encouraging Oncology Data Boosts Investor Optimism

Genmab (GMAB) presented positive Phase 2 data for petosemtamab in head and neck cancer, showing 28.2-month median survival and 63% response rate. It also reported promising results in metastatic colorectal cancer. Genmab partnered with Incyte (INCY) for a Phase 1/2 trial. GMAB shares rose 1.56% to $44.93, a 52-week high.

finance.yahoo.com2 min
OCT 26
$GMABHighAI 9/10

Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial

Genmab's rinatabart sesutecan (Rina-S) showed a 71% reduction in disease progression or death and a 57% reduction in death risk in a Phase 3 ovarian cancer trial, exceeding expectations. Analysts predict it could challenge AbbVie's Elahere. Genmab's stock rose over 8%. The company plans regulatory discussions and potential 2027 U.S. launch.

biospace.com2 min
OCT 26
$GMABMedAI 9/10

Genmab Phase 2 Trial Reports 28.2-Month Cancer Survival

Genmab reported Phase 2 trial results showing 28.2-month median overall survival for petosemtamab plus pembrolizumab in PD-L1-positive head and neck cancer. The combination achieved a 63% response rate and 9.0-month progression-free survival. Genmab plans Phase 3 results in 2026.

grafa.com2 min